Key Figures Q1 2023

SEK m, unless otherwise stated

2023
Jan-Mar

2022
Jan-Mar

% Change

2022
Jan-Dec

Net revenues 159 159 -0.4% 624
Cost of goods sold -29 -28 4.2% -103
Operating expenses -189 -145 30.6% -706
EBIT -59 -13 350.0% -184
EBIT margin, % -37% -8% 29.1% -30%
EBITDA -41 3 -1,567.9% -115
Earnings per share, before dilution, SEK -2 -1 169.6% -5
Earnings per share, after dilution, SEK -2 -1 169.6% -5
Cash flow from operating activities -67 -67 0.0% -157
Cash and invested funds 279 438 -36.3% 352


Net revenues and EBIT per segment Q1 2023

 

Net Revenues

EBIT


SEK m

2023
Jan-Mar

2022
Jan-Mar

2022
Jan-Dec

2023
Jan-Mar

2022
Jan-Mar

2022
Jan-Dec

ZUBSOLV® US 140 139 571 - - -
US Pharma – total 140 139 571 74 84 308
Digital Therapeutics (DTx) product sales 0.0 0.2 0.4 - - -
Digital Therapeutics (DTx) – total 0.0 0.2 0.4 -36 -43 -189
Abstral® royalties 6 12 30 - - -
Edluar® royalties 1 3 10 - - -
ZUBSOLV® - ex US 11 5 12 - - -
HQ & Pipeline - total 19 20 53 -97 -54 -303
Total 159 159 624 -59 -13 -184


Cash flow Q1 2023


SEK m

2023
Jan-Mar

2022
Jan-Mar

2022
Jan-Dec

Cash flow from operating activities -62 -62 -157
Investment activities 83 -6 -235
Financing activities -8 -5 -21
Cash flow (excl exchange rate differences) 14 -73 -413
Cash and cash equivalents 1421 438 1321

1 Cash and cash equivalents excluding invested surplus cash of SEK 142.4 m in short-term assets, certificates of deposits and in US treasuries. As of March 31, 2023, cash and invested funds amounted to SEK 278.9 m (437.8)